MiR-488 is obviously decreased in metastatic/recurrent CRC, which can also refine the chemoresistance and glycolysis of CRC by targeting a key enzyme involved in glucose metabolism, namely, phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) (25). The gene discussed is PFKFB3; the disease is colorectal carcinoma.